» Articles » PMID: 23555923

There is No Association Between MicroRNA Gene Polymorphisms and Risk of Triple Negative Breast Cancer in a Chinese Han Population

Overview
Journal PLoS One
Date 2013 Apr 5
PMID 23555923
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Triple-negative breast cancer (TNBC) is defined by the lack of the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). It is characterized by aggressive behavior, poor prognosis and lack of targeted therapies. MicroRNA (miRNA) as a novel modulator of gene expression has played an important regulatory role in the malignancy. Dysregulation and/or mutation of the miRNAs may also contribute to the TNBC susceptibility since it is associated with the expression of ER, PR and HER2. Single nucleotide polymorphisms (SNPs) in miRNAs may be extremely relevant for TNBC. We tried to validate the hypothesis that genetic variations in miRNA are associated with TNBC development, and identify candidate biomarkers for TNBC susceptibility and clinical treatment. We screened the genetic variants in all miRNA genes listed in the public database miRBase and NCBI. A total of 23 common SNPs in 22 miRNAs, which tagged the known common variants in the Chinese Han people with a minor allele frequency greater than 0.05, were genotyped. This case-control study involved 191 patients with TNBC and 192 healthy female controls. Frequencies of SNPs were compared between cases and controls to identify the SNPs associated with TNBC susceptibility. No significant association was found between TNBC risk and the SNPs in the miRNA genes in the Chinese Han people (P>0.05), but this warrants further studies.

Citing Articles

Effect of rs11614913 Polymorphism on Cancer Susceptibility: Evidence From an Updated Meta-Analysis.

Aziz M, Akter T, Islam M Technol Cancer Res Treat. 2022; 21:15330338221109798.

PMID: 35770306 PMC: 9251994. DOI: 10.1177/15330338221109798.


Genetic Polymorphism rs6505162 in MicroRNA-423 May Not Be Associated with Susceptibility of Breast Cancer: A Systematic Review and Meta-Analysis.

Li Z, Wang J, Chen H, Guo X, Chen X, Wang M J Oncol. 2021; 2021:3003951.

PMID: 34868312 PMC: 8641987. DOI: 10.1155/2021/3003951.


Association between single-nucleotide polymorphisms in miRNA and breast cancer risk: an updated review.

Arancibia T, Morales-Pison S, Maldonado E, Jara L Biol Res. 2021; 54(1):26.

PMID: 34454612 PMC: 8401249. DOI: 10.1186/s40659-021-00349-z.


Evidences from a Systematic Review and Meta-Analysis Unveil the Role of MiRNA Polymorphisms in the Predisposition to Female Neoplasms.

Bastami M, Choupani J, Saadatian Z, Zununi Vahed S, Ouladsahebmadarek E, Mansoori Y Int J Mol Sci. 2019; 20(20).

PMID: 31615040 PMC: 6834313. DOI: 10.3390/ijms20205088.


Association of mir-196a-2 rs11614913 and mir-149 rs2292832 Polymorphisms With Risk of Cancer: An Updated Meta-Analysis.

Choupani J, Nariman-Saleh-Fam Z, Saadatian Z, Ouladsahebmadarek E, Masotti A, Bastami M Front Genet. 2019; 10:186.

PMID: 30930933 PMC: 6429108. DOI: 10.3389/fgene.2019.00186.


References
1.
Yang H, Dinney C, Ye Y, Zhu Y, Grossman H, Wu X . Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 2008; 68(7):2530-7. DOI: 10.1158/0008-5472.CAN-07-5991. View

2.
Saunders M, Liang H, Li W . Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci U S A. 2007; 104(9):3300-5. PMC: 1805605. DOI: 10.1073/pnas.0611347104. View

3.
Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

4.
Zeng Y, Wagner E, Cullen B . Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002; 9(6):1327-33. DOI: 10.1016/s1097-2765(02)00541-5. View

5.
Diederichs S, Haber D . Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res. 2006; 66(12):6097-104. DOI: 10.1158/0008-5472.CAN-06-0537. View